ARDX
Ardelyx Inc
NASDAQ: ARDX · HEALTHCARE · BIOTECHNOLOGY
$6.33
+5.32% today
Updated 2026-04-30
Market cap
$1.47B
P/E ratio
—
P/S ratio
3.62x
EPS (TTM)
$-0.26
Dividend yield
—
52W range
$3 – $8
Volume
3.8M
Ardelyx Inc (ARDX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $21.98M | $1.81M | $13.40M | $-71.84M | $-92.53M | $-65.19M | $-70.27M | $-76.48M | $-81.44M | $-152.55M | $-70.04M | $-89.72M | $-44.81M | $-42.48M |
| Capital expenditures | $128000.00 | $278000.00 | $1.86M | $3.45M | $4.87M | $2.35M | $311000.00 | $325000.00 | $324000.00 | $1.87M | $55000.00 | $344000.00 | $1.01M | $1.49M |
| Depreciation | $675000.00 | $592000.00 | $302000.00 | $829000.00 | $1.29M | $2.64M | $2.68M | $2.50M | $1.82M | $1.44M | $1.14M | $1.29M | $2.06M | — |
| Stock-based comp | $473000.00 | $352000.00 | $1.69M | $2.63M | $5.32M | $9.59M | $9.23M | $9.94M | $10.58M | $12.04M | $10.75M | $13.53M | $37.38M | $48.96M |
| Free cash flow | $21.85M | $1.53M | $11.54M | $-75.29M | $-97.40M | $-67.55M | $-70.58M | $-76.81M | $-81.76M | $-154.42M | $-70.10M | $-90.06M | $-45.82M | $-43.98M |
| Investing cash flow | $-128000.00 | $-278000.00 | $-1.86M | $-3.45M | $-131.08M | $65.29M | $-29.89M | $23.37M | $-31.44M | $50.95M | $18.41M | $-131.25M | $-18.32M | — |
| Financing cash flow | $270000.00 | $-1000.00 | $61.31M | $75.01M | $191.20M | $685000.00 | $103.55M | $155.48M | $22.78M | $83.00M | $75.34M | $146.29M | $106.59M | — |
| Dividends paid | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | $106000.00 | — | $25.89M | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $72.85M | $-282000.00 | $-32.41M | $785000.00 | $3.38M | $102.36M | $-90.10M | $-18.60M | $23.71M | — | — | — |